Aptose Biosciences

146 articles with Aptose Biosciences

• Aptose To Release Third Quarter Ended September 30, 2017 Financial Results and Hold Conference Call on November 14, 2017

  11/7/2017

  The company intends to host a conference call the same day at 5:00 p.m. ET to discuss the financial results.

• Aptose Enters Into $15.5M Common Shares Purchase Agreement With Aspire Capital Fund

  10/30/2017

  Aptose also provided a corporate update on the development of its two hematology drug candidates.

• Aptose Biosciences And CrystalGenomics Announce Issuance Of U.S. Patent For CG’806

  9/12/2017

• Aptose Biosciences Reports Results For The Second Quarter Ended June 30, 2017

  8/9/2017

• Aptose Biosciences To Release Second Quarter Ended June 30, 2017 Financial Results And Hold Conference Call On August 8, 2017

  8/1/2017

• Aptose Biosciences Announces Results Of Annual Meeting Of Shareholders

  6/7/2017

• Aptose Biosciences Reports Results for the First Quarter Ended March 31, 2017

  5/12/2017

• Preclinical Data On Aptose Biosciences FLT3/BTK Inhibitor CG’806 Presented At AACR Hematologic Malignancies Meeting

  5/8/2017

• Oregon Health & Science University (OHSU) And Aptose Biosciences Present CG’806 Preclinical Data Demonstrating Potent Activity Against Patient Samples At AACR Hematologic Malignancies Meeting

  5/8/2017

• Aptose Biosciences To Release First Quarter Ended March 31, 2017 Financial Results And Hold Conference Call On May 11, 2017

  4/24/2017

• Aptose Biosciences Provides Update On Apto-253 Development

  12/29/2016

• Aptose Biosciences And CrystalGenomics Announce Exclusive Agreement For Non-Covalent BTK / FLT3 / AURK Inhibitor

  6/8/2016

• Aptose Biosciences Reports Results For The First Quarter Ended March 31, 2016

  5/11/2016

• Aptose Biosciences To Participate In Upcoming Investor Conferences

  3/4/2016

• H. Lee Moffitt Cancer Center & Research Institute And Aptose Biosciences To Present Data On A Novel Class Of Dual-Targeting Bromodomain / Kinase Inhibitors At 57th Annual American Society of Hematology Meeting

  12/3/2015

• Aptose Biosciences To Participate In Upcoming Investor Conferences

  12/1/2015

• Aptose Biosciences Suspends Dosing of Lead Drug APTO-253

  11/20/2015

• Aptose Biosciences Reports Results For The Third Quarter Ended September 30, 2015

  11/11/2015

• Aptose Biosciences Announces Collaborations For New Multi-Targeting Epigenetic Therapeutic Agents

  11/10/2015

• Beat AML & Aptose Biosciences Present Data For APTO-253 At The 57th American Society of Hematology Annual Meeting

  11/5/2015